EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, HCW Biologics's enterprise value is $27.87 Mil.
HCW Biologics's Revenue for the trailing twelve months (TTM) ended in Mar. 2025 was $1.45 Mil. Therefore, HCW Biologics's EV-to-Revenue for today is 19.29.
The historical rank and industry rank for HCW Biologics's EV-to-Revenue or its related term are showing as below:
HCWB'
s EV-to-Revenue Range Over the Past 10 Years
Min: 2.75 Med: 11.56 Max: 49.94
Current: 19.29
During the past 6 years, the highest EV-to-Revenue of HCW Biologics was 49.94. The lowest was 2.75. And the median was 11.56.
HCWB's EV-to-Revenue is ranked worse than 69.21% of 997
companies
in the Biotechnology industry
Industry Median: 7.28
vs HCWB: 19.29
As of today (2025-05-27), HCW Biologics's stock price is $8.00.
HCW Biologics's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2025 was $1.48. Therefore, HCW Biologics's PS Ratio for today is 5.40.
HCW Biologics EV-to-Revenue Historical Data
The historical data trend for HCW Biologics's EV-to-Revenue can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of HCW Biologics's EV-to-Revenue
For the Biotechnology subindustry, HCW Biologics's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
HCW Biologics's EV-to-Revenue Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, HCW Biologics's EV-to-Revenue distribution charts can be found below:
* The bar in red indicates where HCW Biologics's EV-to-Revenue falls into.
HCW Biologics's current Enterprise Value is $27.87 Mil.
HCW Biologics's Revenue for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $1.45 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
HCW Biologics's share price for today is $8.00.
HCW Biologics's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $1.48.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
HCW Biologics EV-to-Revenue Related Terms
Thank you for viewing the detailed overview of HCW Biologics's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.
HCW Biologics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen the health span by disrupting the link between chronic, low-grade inflammation and age-related diseases. The company has developed TOBI discovery platform, or Tissue factor-based fusion discovery platform, for the design of category-defining immunotherapeutic drugs. It has selected two molecules as its product candidate; HCW9218 and HCW9302. HCW9218 is a bifunctional immunotherapeutic designed with the capabilities to neutralize transforming growth and stimulate immune cells. HCW9302 is designed to activate and expand regulatory T cells, which deactivate inflammasomes.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
HCWB has been successfully added to your 